US Patent Issued to CRISPR Therapeutics on July 1 for "Genetically engineered T cells having improved persistence in culture" (Massachusetts Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,344,656, issued on July 1, was assigned to CRISPR Therapeutics AG (Zug, Switzerland).

"Genetically engineered T cells having improved persistence in culture" was invented by Jonathan Alexander Terrett (Cambridge, Mass.), Demetrios Kalaitzidis (Cambridge, Mass.) and Hanspeter Waldner (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetic...